Pre-Clinical Testing Ramping UP.....
Transition busy Hiring Associate Director of Pre-Clinical Research.
So many options for Mgnt. to consider for the next Drug to advance to pre-clinicals........My guess is that the 'Minozac' small molecule is undergoing or about to undergo additional Pre-clinical Toxicity to support its application to the FDA for initiating a Phasel safety study in healthy volunteers.
Being that in animal studies 'Minozac' has shown to prevent neuronal dysfunction in pre-clinical testing targeting Alzheimers and Brain Trauma its higher priority seems rather academic to me.
Other options are emerging from the Drug Discovery Program including Breast Cancer and Osteoperosis. Transition is also targeting large indications such as Hypertension and Anemia. Dr. Cruz may surprise a few by advancing one of the Lead Molecules into Pre-clinicals or announcing results from pre-clinicals already performed and patent pending.
But imo Minozac will see the attention it deserves soon........
TTH = Robust Pipeline.
TTH = Robust R&D.
TTH = Robust Pre-Clinical.
TTH = Robust Treasury.
TTH = Increased SV
G1+DDP-IV Inhibitors ......Progressing Rapidly through Pre-Clinicals. Perhaps our next partnership is dependant upon those Pre-Clinical Results if some Co. is looking at taking on the Gastrin Based Therapys as a very Large Package Deal.........that would be speculation at this juncture.
Too Risky for some. High Risk--HUGE Reward!!
!!The Excitement Awards!! Tomorrow.